Also known as: Faslodex (brand)
Fulvestrant is a selective estrogen receptor degrader (SERD) used in the treatment of hormone receptor-positive (HR+) metastatic breast cancer in postmenopausal women. It binds to and degrades the estrogen receptor, blocking estrogen-driven tumor growth.
Mediocon Inc supplies Fulvestrant IP/BP/EP/USP as a high-purity oncology active pharmaceutical ingredient for licensed parenteral formulation manufacturers. With extensive GMP quality controls and multi-pharmacopoeial compliance, our Fulvestrant supports global regulatory submissions.
Key Features
Applications
Why Choose Mediocon
| Parameter | Specification |
|---|---|
| Assay | NLT 98.0% & NMT 102.0% |
| Water Content | NMT 1.0% |
| Heavy Metals | NMT 10 ppm |
| Residual Solvents | Complies ICH Q3C |
| Microbial Limits | Complies |
| Identification | HPLC & IR Compliant |
| Specific Rotation | +23° to +27° |
| Packing | 25 kg HDPE drums / as per requirement |
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Fulvestrant (CAS 129453-61-8) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Fulvestrant is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing — identity (IR/HPLC), assay, related substances, residual solvents (ICH Q3C), heavy metals, and microbial limits — before release with a Certificate of Analysis.
Export Markets
Quality & Compliance